Prescribing information (external link)
This promotional event has been organised and funded by Novartis Pharmaceuticals UK Ltd.
Psoriatic Disease in the Spotlight: our UK Rheumatology Event during EULAR 2026
Cosentyx® (secukinumab) is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1 Full indications can be found at the bottom of the page.
Cosentyx Summary of Product Characteristics (SmPC) can be found here.
An evening symposium, with dinner provided for those joining in person, featuring
Agenda | ||
4 June 2026 | ||
19:0019:30 Hrs | Image
| An international perspective on getting control back after a loss of treatment responseProf. Frank Behrens |
19:3020:00 Hrs | Image
| Is Psoriatic Disease driven by Non-Inflammatory or Pro-Inflammatory mechanisms?Prof. Dennis McGonagle |
20:3021:00 Hrs | Image
| Psoriatic Disease in the Spotlight: An Interactive Expert DiscussionProf. Pauline Ho |
Resources
Therapeutic Indications1
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
AS, ankylosing spondylitis; ERA; enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, summary of product characteristics.
Reference
Cosentyx® (secukinumab) Summary of Product Characteristics.
UK | April 2026 | FA-11615523
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
